Liu et al., 2012 - Google Patents
Downregulation of FGL 2/prothrombinase delays HCCLM 6 xenograft tumour growth and decreases tumour angiogenesisLiu et al., 2012
- Document ID
- 558504152285679699
- Author
- Liu Y
- Xu L
- Zeng Q
- Wang J
- Wang M
- Xi D
- Wang X
- Yang D
- Luo X
- Ning Q
- Publication year
- Publication venue
- Liver international
External Links
Snippet
Background Fibrinogen‐like protein 2 (FGL 2), which directly generates thrombin from prothrombin without activation of the conventional coagulation cascade, was shown to be overexpressed in various human malignant tumours. Aims Herein, we aimed to investigate …
- 230000012010 growth 0 title abstract description 29
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Downregulation of FGL 2/prothrombinase delays HCCLM 6 xenograft tumour growth and decreases tumour angiogenesis | |
| Li et al. | ENO1 promotes lung cancer metastasis via HGFR and WNT signaling–driven epithelial-to-mesenchymal transition | |
| Joo et al. | MET signaling regulates glioblastoma stem cells | |
| Schwab et al. | Polyol pathway links glucose metabolism to the aggressiveness of cancer cells | |
| Tiwari et al. | Metabolically activated adipose tissue macrophages link obesity to triple-negative breast cancer | |
| Teichert et al. | Pericyte-expressed Tie2 controls angiogenesis and vessel maturation | |
| Zhou et al. | All-trans retinoic acid prevents osteosarcoma metastasis by inhibiting M2 polarization of tumor-associated macrophages | |
| Liou et al. | Mutant KRAS–induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions | |
| Fofaria et al. | STAT3 induces anoikis resistance, promotes cell invasion and metastatic potential in pancreatic cancer cells | |
| Hongu et al. | Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs | |
| Xu et al. | HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma | |
| Wculek et al. | Neutrophils support lung colonization of metastasis-initiating breast cancer cells | |
| Zhang et al. | Endothelial cell-secreted EGF induces epithelial to mesenchymal transition and endows head and neck cancer cells with stem-like phenotype | |
| Wang et al. | CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway | |
| Lee et al. | Alpha-smooth muscle actin (ACTA2) is required for metastatic potential of human lung adenocarcinoma | |
| Bing et al. | Simvastatin improves the homing of BMSC s via the PI 3K/AKT/miR‐9 pathway | |
| Lesina et al. | Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer | |
| Tu et al. | Upregulation of SATB 1 promotes tumor growth and metastasis in liver cancer | |
| Casazza et al. | Tumour growth inhibition and anti‐metastatic activity of a mutated furin‐resistant Semaphorin 3E isoform | |
| Acuff et al. | Matrix metalloproteinase-9 from bone marrow–derived cells contributes to survival but not growth of tumor cells in the lung microenvironment | |
| Brantley et al. | Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas | |
| Su et al. | Differential expression of CXCR4 is associated with the metastatic potential of human non–small cell lung cancer cells | |
| Rovida et al. | The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma | |
| Gao et al. | Chemokine CCL15 mediates migration of human bone marrow-derived mesenchymal stem cells toward hepatocellular carcinoma | |
| Nisancioglu et al. | The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade |